agilon health, Inc. (AGL) intrinsic value & 10-year financials
agilon health, Inc. (AGL) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 39.8% a year to $5.9B, with an average return on invested capital of 10.5%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $85.12
- Market cap
- $35.2B
- Revenue (FY2025)
- $5.9B
- Revenue growth (8-yr CAGR)
- 39.8%
- ROIC (10-yr avg)
- 10.5%
- Free cash flow (FY2025)
- -$119.0M
AGL 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $5.9B | -$391.3M | — | -$119.0M | -7.8% | -295.0% |
| FY2024 | $6.1B | -$260.2M | — | -$71.0M | -4.8% | -63.0% |
| FY2023 | $4.3B | -$262.6M | — | -$172.0M | -5.4% | -38.7% |
| FY2022 | $2.7B | -$106.6M | — | -$146.2M | -4.4% | -34.2% |
| FY2021 | $1.8B | -$406.5M | — | -$154.7M | -21.5% | 374.9% |
| FY2020 | $1.2B | -$60.1M | — | -$55.0M | -4.7% | 17.8% |
| FY2019 | $794.4M | -$282.6M | — | -$106.8M | -13.4% | 111.8% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
agilon health, inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
agilon health, inc. has historically struggled to out-earn its cost of capital, averaging just -19.5% ROIC.
agilon health, inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, agilon health, inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-31.40 per share.